BioPharma Today

Sun Pharma Managing Director Dilip Shanghvi On Building Its U.S. Base: An Interview With PharmAsia News (Part 2 of 2)

Full article reprinted from PharmAsia News February 24, 2009

With a robust business strategy of strengthening its U.S. operations, India's Sun Pharmaceutical has emerged as the most valued Indian drug company. As stock markets hammered down valuations for other top Indian drug companies like Ranbaxy, Dr. Reddy's and Cipla, analysts have largely held Sun's valuations steady. In a rare interview with PharmAsia News' Indian bureau, Sun Pharmaceutical Chairman and Managing Director Dilip Shanghvi shares his thoughts on the long term goals for the company and speaks out on the tangle that his company is engaged in to acquire Israeli drug maker Taro. Read on...

Can A REMS Save Raptiva? Tysabri-Style Program Would Mean Restrictions

Full article reprinted from "The Pink Sheet" February 24, 2009

Ongoing discussions about a risk management plan for Genentech's Raptiva (efalizumab) may provide an avenue to maintain the psoriasis drug's commercial viability, despite its safety problems. Read on...
 

What New Her2 Tests Say about Personalized Medicine

Article preview from Start-Up February 24, 2009

Traditional diagnostic tests for Her2 (the target of the drug Herceptin) have well-documented failings. In July, Monogram Biosciences launched a new Her2 test, and two months later, Genomic Health added Her2 status information to its breast cancer test. Read on...

White House May Battle For Sebelius As HHS Chief With Nomination In Trouble

Article reprinted from "The Pink Sheet" DAILY February 24, 2009

The White House may intervene to try to salvage the nomination of Kansas Gov. Kathleen Sebelius for HHS Secretary. Read more

Side Effects Dampen Neurologists’ Enthusiasm For Novel MS Drugs

Article reprinted from "The Pink Sheet" February 17, 2009

With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development - from the first oral options to infrequently administered biologics - the treatment paradigm for the debilitating disease appears on the cusp of significant change. Read more now...

 

Is FDA More Conservative Than EMEA? FDA Says No; Investors Weigh In

Article reprinted from The RPM Report February 17, 2008

Office of New Drugs director John Jenkins debates the perception that FDA approves fewer products than its regulatory counterparts in Europe. But some investors see troubling trends in data presented by the agency at the FDA/CMS Summit. Find out why...

The Asia Corner - From the Editors of PharmAsia News

The Asia Corner - From the Editors of PharmAsia News February 17, 2009

In this BioPharma Today feature, the editors of PharmAsia News take a closer look each week at the most important biopharma developments from China, India, Japan and the Pacific Rim.

Read today's features...

Symphony's Project Financing Model Adapts

Article preview from IN VIVO February 17, 2008

As Wall Street fails to significantly reward companies with strong clinical news, the fall-out also affects the project financiers, like Symphony Capital -- an increasingly important alternative to traditional equity or alliance financing. On one hand, the hard times make Symphony's expensive-looking capital increasingly attractive to biotechs, including companies that once would have had plenty of other financing alternatives. On the other, Symphony's model is shifting more toward equity investing. It's still financing projects, but it's padding its upside with a lot more cheap stock. Read on...

Secretary Sebelius? Key HHS Departure May Signal HHS Secretary Choice Is Made

Full article reprinted "The Pink Sheet" DAILY February 17, 2009

Kansas Gov. Sebelius appears to be the administration’s focus following Daschle withdrawal. Read more...

HHS Staff Appointments Bring Ties To HELP Committee, Sen. Baucus

Article reprinted from "The Pink Sheet" DAILY February 10, 2009

Details of responsibilities for seven connected health care policy pros are still being worked out. Read more...